Mangoceuticals, Inc.

Name: Mangoceuticals, Inc. standardized financial statements, quarterly
Creator: Listed

MGRXNasdaqCIK 1938046HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$68.8k, Q2 FY2026

Operating income−$1.0m, Q2 FY2026

Net income−$1.3m, Q2 FY2026

Mangoceuticals, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	245	244	214	163	133	105	109	168	84.2	94.4	67.9	68.8
Cost of revenue	$k	52.2	53.4	20.8	29.7	21.5	21.3	24.7	18.8	2.4	8.5	8.2	10.4
Gross profit	$k	145	143	147	69.8	82.7	80.1	62.1	89.9	50.9	47.5	29.0	44.2
Operating income	$k	(1,799)	(2,568)	(2,368)	(2,169)	(1,758)	(1,678)	(4,576)	(5,268)	(7,543)	(368)	(3,126)	(1,033)
Interest expense	$k	0.0	0.0	not reported	not reported	not reported	not reported	(13.7)	21.7	75.9	19.7	not reported	not reported
Net income	$k	(1,799)	(2,568)	(2,368)	(2,391)	(1,999)	(1,948)	(4,839)	(5,416)	(7,618)	(2,770)	(3,403)	(1,313)
Diluted EPS	$ per share	(1.70)	not reported	(1.50)	(1.37)	(1.14)	not reported	(1.12)	(0.57)	(0.69)	not reported	(0.22)	(0.09)
Basic EPS	$ per share	(1.70)	not reported	(1.50)	(1.37)	(1.14)	not reported	(1.12)	(0.57)	(0.69)	not reported	(0.22)	(0.09)

Balance sheet

Cash and equivalents$228.7k, Q2 FY2026

Shareholders' equity$12.5m, Q2 FY2026

Mangoceuticals, Inc., balance sheet, quarterly
Line item	Unit	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	period not labelled2025-02-11	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	0.7	0.0	0.5	0.1	0.1	0.3	0.1	0.1	0.5	1.5	0.2	0.2
Current assets	$m	0.8	0.1	0.5	0.1	0.1	not reported	0.2	0.1	0.6	1.5	0.2	0.2
Total assets	$m	1.1	0.3	15.2	14.8	15.4	not reported	21.8	20.8	16.5	16.1	14.4	14.2
Current liabilities	$m	0.2	1.2	1.4	1.4	1.4	not reported	1.5	1.6	0.8	0.9	0.7	1.4
Total liabilities	$m	0.3	1.3	1.4	1.4	1.4	not reported	1.5	1.6	0.8	0.9	1.0	1.6
Shareholders' equity	$m	0.8	(1.0)	13.8	13.4	13.9	not reported	20.3	19.2	15.7	15.2	13.5	12.5

Cash flow

Operating cash flow−$260.5k, Q2 FY2026

Capital expenditure$0, Q4 FY2023

Mangoceuticals, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(1,711)	(1,698)	(991)	(1,577)	(1,166)	(1,130)	(2,275)	(1,256)	(1,241)	(1,078)	(1,311)	(261)
Capital expenditure	$k	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)17.12m, Q2 FY2026

Mangoceuticals, Inc., shares, quarterly
Line item	Unit	period not labelled2022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	10.0	11.3	15.8	1.1	1.6	1.7	2.0	4.6	10.0	11.5	16.5	17.1

Shares outstanding: 21.57m at Aug 13, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.